NO20015501L - Anvendelse av bionedbrytbare mikrokuler som frigjör et anticancertmiddel for behandling glioblastom - Google Patents

Anvendelse av bionedbrytbare mikrokuler som frigjör et anticancertmiddel for behandling glioblastom

Info

Publication number
NO20015501L
NO20015501L NO20015501A NO20015501A NO20015501L NO 20015501 L NO20015501 L NO 20015501L NO 20015501 A NO20015501 A NO 20015501A NO 20015501 A NO20015501 A NO 20015501A NO 20015501 L NO20015501 L NO 20015501L
Authority
NO
Norway
Prior art keywords
biodegradable microspheres
microspheres
glioblastoma
release
treatment
Prior art date
Application number
NO20015501A
Other languages
English (en)
Other versions
NO331686B1 (no
NO20015501D0 (no
Inventor
Nathalie Faisant
Jean Pierre Benoit
Philippe Menei
Original Assignee
Ethypharm Lab Prod Ethiques
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethypharm Lab Prod Ethiques filed Critical Ethypharm Lab Prod Ethiques
Publication of NO20015501D0 publication Critical patent/NO20015501D0/no
Publication of NO20015501L publication Critical patent/NO20015501L/no
Publication of NO331686B1 publication Critical patent/NO331686B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Foreliggende oppfinnelse angår bruken av bionedbrytbare mikrokuler som frigjør et radiosensitiverende anticancermiddel for fremstilling av et medikament som kan brukes samtidig med, separat fra eller brukt over tid, med en radioterapi for behandling av glioblastom. Bruken av nevnte bionedbrytbare mikrokuler ifølge foreliggende oppfinnelse resulterer i en pasientoverlevelsestid på minst 90 uker, og hvor en terapeutisk effektiv konsentrasjon blir opprettholdt i det parenchymatøse området i hele dette tidsrom. Mikrokulene inneholder fortrinnsvis 5-fluoruracil belagt med poly(d,l-melkesyre-co-glykolinsyre). Mikrokulene blir implantert i veggene omkring operasjonsstedet etter ekserese av tumoren, ved intravevsinjeksjon. Den radioterapi som settes inn mot tumoren er dosert med 60 Gy over ca 6 uker. Oppfinnelsen angår også en fremgangsmåte for fremstilling av bionedbrytbare mikrokuler ved en emulsjons-ekstraksjon, og en suspensjon som inneholder de bionedbrytbare mikrokuler som er fremstilt ved denne fremgangsmåten.
NO20015501A 1999-05-17 2001-11-09 Fremgangsmate for a fremstille bionedbrytbare mikrokuler som inneholder et anticancermiddel og er belagt med en polymer, suspensjoninneholdende disse mikrokulene og anvendelse av mikrokulene ifremstilling av et medisinsk produkt til behandlingen av glioblastom. NO331686B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9906207A FR2793684B1 (fr) 1999-05-17 1999-05-17 Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant
PCT/FR2000/001315 WO2000069413A1 (fr) 1999-05-17 2000-05-17 Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome

Publications (3)

Publication Number Publication Date
NO20015501D0 NO20015501D0 (no) 2001-11-09
NO20015501L true NO20015501L (no) 2002-01-09
NO331686B1 NO331686B1 (no) 2012-02-20

Family

ID=9545636

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015501A NO331686B1 (no) 1999-05-17 2001-11-09 Fremgangsmate for a fremstille bionedbrytbare mikrokuler som inneholder et anticancermiddel og er belagt med en polymer, suspensjoninneholdende disse mikrokulene og anvendelse av mikrokulene ifremstilling av et medisinsk produkt til behandlingen av glioblastom.

Country Status (30)

Country Link
US (2) US6803052B2 (no)
EP (2) EP1053746B1 (no)
JP (1) JP5230045B2 (no)
KR (1) KR100649948B1 (no)
CN (1) CN1210020C (no)
AR (1) AR024008A1 (no)
AT (1) ATE228353T1 (no)
AU (1) AU775320B2 (no)
BG (1) BG64936B1 (no)
BR (1) BR0010648A (no)
CA (1) CA2388656C (no)
CZ (1) CZ20014137A3 (no)
DE (1) DE60000842T2 (no)
DK (1) DK1053746T3 (no)
EA (1) EA004943B1 (no)
ES (1) ES2185544T3 (no)
FR (1) FR2793684B1 (no)
HK (1) HK1047044B (no)
HU (1) HUP0201224A3 (no)
IL (2) IL146467A0 (no)
MX (1) MXPA01011919A (no)
NO (1) NO331686B1 (no)
NZ (1) NZ515515A (no)
PL (1) PL201614B1 (no)
PT (1) PT1053746E (no)
SI (1) SI1053746T1 (no)
SK (1) SK16342001A3 (no)
TW (1) TWI229608B (no)
WO (1) WO2000069413A1 (no)
ZA (1) ZA200109415B (no)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4695318B2 (ja) 1999-08-05 2011-06-08 エムアーペー メディツィンテクノロジー ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 呼気ガスを供給する装置、加湿装置、呼吸用チューブ接続デバイス、呼吸用チューブ及び接続構造
AUPR098300A0 (en) 2000-10-25 2000-11-16 Sirtex Medical Limited Polymer based radionuclide containing microspheres
JP2002154963A (ja) * 2000-11-14 2002-05-28 Yakult Honsha Co Ltd 徐放性抗腫瘍剤
US20020081339A1 (en) * 2000-12-22 2002-06-27 Philippe Menei Treatment of inoperable tumors by stereotactic injection of microspheres
CN1537018A (zh) 2001-05-23 2004-10-13 田边制药株式会社 一种用于软骨疾病再生治疗的组合物
EP1389468A4 (en) * 2001-05-23 2007-01-10 Tanabe Seiyaku Co COMPOSITIONS FOR PROMOTING BONE FRACTURE HEALING
EP1411861B1 (en) 2001-06-29 2012-04-04 Medgraft Microtech, Inc. Biodegradable injectable implants and related methods of manufacture and use
UA77999C2 (en) * 2001-12-10 2007-02-15 Thymosin-alpha 1 for treatment of malignant glioblastoma
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
US8986737B2 (en) 2002-09-05 2015-03-24 Wm. Marsh Rice University Antibiotic microspheres for treatment and prevention of osteomyelitis and enhancement of bone regrowth
DE202004021798U1 (de) 2003-06-20 2011-02-10 ResMed Ltd., Bella Vista Atemgasvorrichtung mit Befeuchter
US20070026005A1 (en) * 2003-09-09 2007-02-01 Sung Young C Vaccine composition comprising il-12 adjuvant encapsulated in controlled-release microsphere
WO2005089398A2 (en) * 2004-03-18 2005-09-29 St. Luke's Hospital Method for the delivery of sustained release agents
JP4929159B2 (ja) * 2004-04-16 2012-05-09 ヌーヴ セラピュティクス、インコーポレイテッド 画像誘導組織切除を改善するための装置
US8088413B2 (en) * 2004-04-16 2012-01-03 Nuvue Therapeutics, Inc. Methods for improved cryo-chemotherapy tissue ablation
EP3085361A1 (en) 2004-09-07 2016-10-26 Biocompatibles UK Limited Compositions comprising camptothecins in microspheres
US8702580B2 (en) * 2004-10-06 2014-04-22 Brainlab Ag Method and device for assisting in a tissue treatment
CN100386115C (zh) * 2004-10-14 2008-05-07 孔庆忠 一种抗癌药物组合物
CN1299685C (zh) * 2005-01-26 2007-02-14 上海大学 氟尿嘧啶载药微球及其制备方法
CN100340297C (zh) * 2005-02-03 2007-10-03 山东蓝金生物工程有限公司 抗癌体内植入剂
CN100464785C (zh) * 2005-08-30 2009-03-04 孔庆忠 一种抗癌药物缓释注射剂及其应用
CN1923282B (zh) * 2005-08-30 2010-05-05 孔庆忠 一种含激素类药物的抗癌缓释注射剂
CN1923281B (zh) * 2005-08-30 2010-05-05 孔庆忠 一种含植物生物碱的抗癌缓释注射剂
CN100500214C (zh) * 2006-01-09 2009-06-17 济南帅华医药科技有限公司 抗癌药物缓释注射剂
CN100563711C (zh) * 2006-01-18 2009-12-02 济南帅华医药科技有限公司 一种抗癌缓释注射剂
CN100500215C (zh) * 2006-01-23 2009-06-17 济南帅华医药科技有限公司 含氨甲喋呤及其增效剂的缓释注射剂
CN100531715C (zh) * 2006-01-23 2009-08-26 济南帅华医药科技有限公司 氨甲喋呤缓释注射剂
CN100531717C (zh) * 2006-01-23 2009-08-26 济南帅华医药科技有限公司 含氨甲喋呤增效剂的抗癌缓释剂
CN1923173B (zh) * 2006-02-24 2010-05-19 济南康泉医药科技有限公司 一种同载抗癌抗生素及其增效剂的抗癌药物缓释剂
CN100486560C (zh) * 2006-03-06 2009-05-13 济南康泉医药科技有限公司 一种含血管抑制剂的复方抗癌缓释注射剂
WO2007105218A2 (en) * 2006-03-14 2007-09-20 Yeda Research And Development Co. Ltd. Composition and method for brain tumor therapy
CN100464736C (zh) * 2006-03-17 2009-03-04 山东蓝金生物工程有限公司 同载抗代谢药物及其增效剂的抗癌缓释注射剂
EP1985286A1 (en) * 2007-04-24 2008-10-29 Biocompatibles UK Limited Microspheres for treatment of brain tumours
RU2664698C2 (ru) 2011-12-13 2018-08-21 Энджинеик Молекьюлар Деливери Пти Лтд Полученные из бактерий интактные мини-клетки для доставки лекарственных средств к опухолям мозга
US10342769B2 (en) 2014-11-14 2019-07-09 Navinta Iii Inc Carmustine pharmaceutical composition
WO2017083717A1 (en) * 2015-11-11 2017-05-18 Qrono, Inc. Sustained release pharmaceutical compositions and methods of use
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
WO2021113638A1 (en) 2019-12-05 2021-06-10 West Virginia University Protein-loaded plga nanospheres
JP7761567B2 (ja) 2020-02-18 2025-10-28 ノヴォ ノルディスク アー／エス 医薬製剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
NZ260909A (en) * 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
JP2001502323A (ja) * 1996-10-16 2001-02-20 リジェネロン ファーマシューティカルズ，インコーポレイテッド 成長因子の送達を増強する方法
WO1998043977A1 (en) * 1997-03-31 1998-10-08 Toray Industries, Inc. Quinolinomorphinane derivatives and medicinal use thereof
AU745324B2 (en) * 1997-10-14 2002-03-21 Cenes Pharmaceuticals, Inc. Therapeutic methods comprising use of a neuregulin

Also Published As

Publication number Publication date
IL146467A (en) 2006-06-11
DK1053746T3 (da) 2003-03-31
BR0010648A (pt) 2002-02-19
NO331686B1 (no) 2012-02-20
EA004943B1 (ru) 2004-10-28
US6803052B2 (en) 2004-10-12
BG64936B1 (bg) 2006-10-31
US7041241B2 (en) 2006-05-09
US20020051749A1 (en) 2002-05-02
NZ515515A (en) 2004-02-27
IL146467A0 (en) 2002-07-25
CN1210020C (zh) 2005-07-13
CA2388656A1 (fr) 2000-11-23
HK1047044A1 (en) 2003-02-07
AU4764100A (en) 2000-12-05
EP1053746B1 (fr) 2002-11-27
DE60000842D1 (de) 2003-01-09
HUP0201224A3 (en) 2004-05-28
TWI229608B (en) 2005-03-21
SI1053746T1 (en) 2003-04-30
HUP0201224A2 (hu) 2002-11-28
AU775320B2 (en) 2004-07-29
AR024008A1 (es) 2002-09-04
KR100649948B1 (ko) 2006-11-24
MXPA01011919A (es) 2002-05-06
HK1047044B (zh) 2005-12-23
PL352372A1 (en) 2003-08-25
ATE228353T1 (de) 2002-12-15
BG106106A (en) 2002-05-31
FR2793684A1 (fr) 2000-11-24
JP2002544219A (ja) 2002-12-24
JP5230045B2 (ja) 2013-07-10
ES2185544T3 (es) 2003-05-01
EP1053746A1 (fr) 2000-11-22
KR20020000178A (ko) 2002-01-04
CZ20014137A3 (cs) 2002-06-12
WO2000069413A1 (fr) 2000-11-23
FR2793684B1 (fr) 2001-08-10
NO20015501D0 (no) 2001-11-09
PT1053746E (pt) 2003-04-30
ZA200109415B (en) 2003-01-29
CN1356892A (zh) 2002-07-03
US20030175356A1 (en) 2003-09-18
CA2388656C (fr) 2011-04-26
PL201614B1 (pl) 2009-04-30
EP1228755A1 (fr) 2002-08-07
EA200101206A1 (ru) 2002-04-25
SK16342001A3 (sk) 2002-08-06
DE60000842T2 (de) 2003-08-28

Similar Documents

Publication Publication Date Title
NO20015501L (no) Anvendelse av bionedbrytbare mikrokuler som frigjör et anticancertmiddel for behandling glioblastom
CA2221356C (en) Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
Johnson et al. Controlled release of neurotrophin‐3 from fibrin‐based tissue engineering scaffolds enhances neural fiber sprouting following subacute spinal cord injury
JP2021107420A (ja) 埋込み型薬物送達組成物およびその使用法
US20030220280A1 (en) Schwann cell bridge implants and phosphodiesterase inhibitors to stimulate CNS nerve regeneration
JP2016047830A (ja) ジアルキルフマレート含有薬剤調合物
RU94036778A (ru) Фармацевтические композиции, способы лечения, способ диагностики, способы идентификации, рецепторы, клетки, нуклеиновые кислоты, соединения, антитела, агент связывания рецептора, способ модуляции экспрессии рецептора, способ уничтожения клетки
EP3796895B1 (en) Biomimetic vesicles and uses thereof
Douglas et al. The respiratory stimulant action of 5-hydroxytryptamine (serotonin) in the dog
JPH10158169A (ja) 塩化トロスピウムを含んだ医薬製剤、その調整方法および使用方法
Chen et al. Preparation of adriamycin gelatin microsphere‐loaded decellularized periosteum that is cytotoxic to human osteosarcoma cells
US20120035531A1 (en) On-demand and reversible drug release by external cue
DE60123117T2 (de) Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs
US20090098187A1 (en) Composition And Its Use For The Manufacture Of A Medicament For Treating, Prophylactically Treating, Preventing Cancer And/Or Infections In The Urinary Tract
JPH02500668A (ja) 粘膜用局部的放射線防護ゲル
RU2335539C2 (ru) Фармацевтический препарат и способ лечения злокачественных опухолей у человека с помощью аргининовой депривации
HU206186B (en) Process for producing pharmaceutical compositions comprising amino acid derivatives having ace-inhibiting effect
DE69021405D1 (de) System zur gesteuerten Freisetzung von Wirkstoffen sowie Verfahren zu dessen Herstellung.
RU2432948C2 (ru) Применение активаторов растворимой гуанилатциклазы для лечения нарушений кровоснабжения
RU2166945C1 (ru) Радиосенсибилизирующее вещество для лечения онкологических заболеваний
RU2375066C2 (ru) Способ профилактики ранних послеоперационных тромбоэмболических осложнений
Shamiss et al. The role of atrial natriuretic peptide in the diuretic effect of Ca2+ entry blockers
AR005724A1 (es) Derivados de ureido biologicamente activos utiles en el tratamiento de esclerosis multiple
CN101879143A (zh) 一种含有抗帕金森病药物的微球组合药物及其应用
RU2328309C1 (ru) Способ повышения биодоступности лекарственных средств

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees